RE:nr-- this makes it now clear the voucher $ is very near... This press release doesn't mean sale of PRV is any closer, you dumba$$. Management guidance was sometime in 2021 and they pay plasma division expenses until they sell it
tommyjones1 wrote:
nr-- this makes it now clear to this pumper that the voucher $ is very near...but it does nothing to make voucher sale any closer.
Read latest NR: FDA issue voucher has to be settled before closing of deal per NR friday. It is a condition and not necessarily imminent. Management said on Q1 call that they will sell by end of 2021. 1st closing means that the plant is sold to Kedrion so no more manufacturing facility for Liminal..
stockbuphoon wrote:
This press release doesn't mean sale of PRV is any closer, you dumba$$. Management guidance was sometime in 2021 and they pay plasma division expenses until they sell it
tommyjones1 wrote:
LAVAL, QC and CAMBRIDGE, England, July 9, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that it has closed on the previously announced divestment of its plasma-derived therapeutics manufacturing subsidiary to Kedrion S.p.A. ("Kedrion") (the "First Closing"). The manufacturing facility is operated through Liminal BioSciences' subsidiary, Prometic Bioproduction Inc. ("PBP").
The consideration received by Liminal for PBP was USD 5 million, which was received upon closing, subject to adjustments. Liminal will also be entitled to receive 70% of the net proceeds from a sale of the Rare Pediatric Disease Priority Review Voucher ("PRV") by its subsidiary, Prometic Biotherapeutics Inc. ("PBT"), which would be payable to Liminal prior to closing the divestment of its remaining plasma-derived therapeutics business operated through PBT (the "Second Closing"). PBT is the holder of the biological license application ("BLA") for Ryplazim® (plasminogen, human-tvmh) ("Ryplazim®") for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia). The Second Closing is subject to the fulfilment of certain conditions precedent, including the sale of the PRV by PBT.
============
With this FDA ok, we can sell that riplazym voucher...market price is between 80M$-120M$ u.s., so lets say 100M$ u.s., we get 70%.... 70M$ u.s. + 17M$ u.s. we cashed already, around 100M$ can$ , lmnl will be able to execute big time and do more deals like this (sell or partner), we gat some in the oven already. Doyour dd. Dont listen to the clown$ operating on this board. They are here for $$$... accumulation time....